XenImmune Therapeutics

XenImmune Therapeutics is a private, preclinical-stage biotech developing a novel therapeutic platform inspired by transplant rejection biology. The company's technology uses antibody-enzyme fusion proteins to coat solid tumors with foreign sugar antigens, thereby triggering a potent, innate immune attack against the cancer. This approach aims to overcome tumor immune evasion and has demonstrated initial proof-of-concept in vitro and in vivo. The modular platform is designed to be adaptable across multiple solid tumor types with high unmet need.

Proprietary antibody-glycosyltransferase (GT) enzyme fusion proteins designed to 'paint' tumor cells with foreign glyco-antigens (e.g., blood group-like sugars). This leverages the body's pre-existing natural antibodies to trigger a hyperacute rejection-like immune response against the cancer.

XenImmune operates in the highly competitive immuno-oncology space, competing with numerous companies developing T-cell engagers, cancer vaccines, oncolytic viruses, and other modalities to enhance tumor immunogenicity. Its unique mechanism of inducing 'foreign' antigen expression is novel but will face comparisons to other approaches aiming to modulate the tumor microenvironment and antigen presentation.